BESPONSA® (inotuzumab ozogamicin) Official HCP Website
Find info on BESPONSA®, an Rx option for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). See risks & benefits. Find the official home page for …
Inotuzumab ozogamicin - Wikipedia
Inotuzumab ozogamicin, sold under the brand name Besponsa, is an antibody-drug conjugate medication used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia …
Besponsa: Uses, Dosage, Side Effects, Warnings - Drugs.com
Mar 12, 2024 · Besponsa is an antineoplastic biological drug used to treat adults and children aged 1 year and older with a type of blood cancer called CD22-positive B-cell precursor acute …
FDA approves new treatment for adults with relapsed or refractory …
The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic …
BESPONSA™ Description - Pfizer Medical Information
BESPONSA (inotuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free, lyophilized powder for intravenous administration. Each single-dose vial …
BESPONSA™ Dosage and Administration - Pfizer Medical …
Administer by intravenous infusion only. For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8 mg/m 2 per cycle, administered as 3 divided doses on Day 1 …
DailyMed - BESPONSA- inotuzumab ozogamicin injection, …
BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older. 2. …
Besponsa - European Medicines Agency (EMA)
Besponsa is a cancer medicine used to treat a type of blood cancer which affects B cells (a type of white blood cells) called B-cell precursor acute lymphoblastic leukaemia (ALL). Besponsa is …
Besponsa: Side effects, dosage, use with other drugs, and more
Jun 12, 2022 · Besponsa is a brand-name prescription drug approved to treat acute lymphoblastic leukemia in certain adults. Learn about side effects, dosage, and more.
BESPONSA™ Indications and Usage - Pfizer Medical Information
BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.